Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May-Jun;30(3):202-209.
doi: 10.1097/PPO.0000000000000717.

Bone Metastases

Gary J R Cook  1 , Matthew P Thorpe  2
Affiliations
Review

Bone Metastases

Gary J R Cook et al. Cancer J. 2024 May-Jun.

Abstract

Bone metastases occur frequently in common malignancies such as breast and prostate cancer. They are responsible for considerable morbidity and skeletal-related events. Fortunately, there are now several systemic, focal, and targeted therapies that can improve quality and length of life, including radionuclide therapies. It is therefore important that bone metastases can be detected as early as possible and that treatment can be accurately and sensitively monitored. Several bone-specific and tumor-specific single-photon emission computed tomography and positron emission tomography molecular imaging agents are available, for detection and monitoring response to systemic therapeutics, as well as theranostic agents to confirm target expression and predict response to radionuclide therapies.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest and Sources of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

References

    1. D'Oronzo S, Coleman R, Brown J, et al. Metastatic bone disease: pathogenesis and therapeutic option: up-date on bone metastasis management. J Bone Oncol. 2018;15:004–004.
    1. Costa L, Badia X, Chow E, et al. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer. 2008;16:879–889.
    1. Coleman RE. Bone cancer in 2011: prevention and treatment of bone metastases. Nat Rev Clin Oncol. 2011;9:76–78.
    1. Mohan R, Kneebone A, Eade T, et al. Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer. Radiat Oncol. 2023;18:127.
    1. Arvola S, Seppänen M, Timonen KL, et al. Detection of prostate cancer bone metastases with fast whole-body 99mTc-HMDP SPECT/CT using a general-purpose CZT system. EJNMMI Phys. 2022;9:85.

MeSH terms

LinkOut - more resources